1-(4-(phenylsulfonyl)piperazin-1-yl)propan-1-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-(phenylsulfonyl)piperazin-1-yl)propan-1-one
• 英文别名: 1-[4-(Phenylsulfonyl)piperazin-1-yl]propan-1-one；1-[4-(benzenesulfonyl)piperazin-1-yl]propan-1-one
• 化学式: C₁₃H₁₈N₂O₃S
• mdl: MFCD09777995
• 分子量: 282.364
• InChiKey: FKVWUSPJIZZDNL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  66.1
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] USE OF ISOXAZOLINE COMPOUNDS AND COMPOSITIONS IN BLADDER CANCER<br/>[FR] UTILISATION DE COMPOSÉS D'ISOXAZOLINE ET COMPOSITIONS DANS LE CANCER DE LA VESSIE
  申请人：CYTOKINE PHARMASCIENCES INC

  公开号：WO2011091040A1

  公开（公告）日：2011-07-28

  One embodiment provides a method, comprising treating or preventing at least one disease selected from the group consisting of bladder cancer, weight loss accompanying bladder cancer, bone pain accompanying bladder cancer, bladder cancer carcinoma in-situ (CIS), TA stage bladder cancer, T1 stage bladder cancer, T2 stage bladder cancer, T3 stage bladder cancer, T4 stage bladder cancer, lymph node metastasis therefrom, solid organ metastasis therefrom, bony metastasis therefrom, cachexia/anorexia associated with bladder cancer, generalized wasting syndrome associated with bladder cancer, or a combination thereof, by administering to a subject in need thereof one or more compounds described herein, prodrug thereof, salt thereof, or a combination thereof.